{
    "organizations": [],
    "uuid": "3256aaa999e2ebecac6044990d2e6ab9e80d7168",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hungarys-richter-cuts-long-term-es/brief-hungarys-richter-cuts-long-term-esmya-sales-targets-idUSL8N1QH0O6",
    "ord_in_thread": 0,
    "title": "BRIEF-Hungary's Richter cuts long-term Esmya sales targets",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt :\n* HAS LOWERED LONG-TERM SALES TARGETS FOR UTERINE FIBROID MEDICINE ESMYA FOR EUROPEAN UNION AND LATIN AMERICAN MARKETS\n* TO ACCOUNT FOR AN IMPAIRMENT LOSS OF ABOUT 42 BILLION FORINTS ($165.22 MILLION) WITH REGARD TO INTANGIBLE ASSET AND GOODWILL LINKED TO ESMYA\n* 2017 OPERATING AND NET PROFIT WILL “SIGNIFICANTLY FALL BEHIND” AMOUNTS PUBLISHED ON FEB. 12 Further company coverage: ($1 = 254.21 forints) (Reporting by Gergely Szakacs)\n ",
    "published": "2018-02-27T14:04:00.000+02:00",
    "crawled": "2018-02-28T12:46:38.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "richter",
        "gedeon",
        "vegyeszeti",
        "gyar",
        "nyrt",
        "lowered",
        "sale",
        "target",
        "uterine",
        "fibroid",
        "medicine",
        "esmya",
        "european",
        "union",
        "latin",
        "american",
        "market",
        "account",
        "impairment",
        "loss",
        "billion",
        "forint",
        "million",
        "regard",
        "intangible",
        "asset",
        "goodwill",
        "linked",
        "esmya",
        "operating",
        "net",
        "profit",
        "significantly",
        "fall",
        "behind",
        "amount",
        "published",
        "company",
        "coverage",
        "forint",
        "reporting",
        "gergely",
        "szakacs"
    ]
}